Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

The FDA just approved a new nasal application for allergy medicine. Pennsylvania law allows for school nurses to train other ...

The FDA approved dihydroergotamine ... DHE is a migraine-specific acute medication first approved in 1946. It comes in several forms, including nasal sprays, injection, intravenous infusion ...

Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as "acute repetitive ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray ... 15 and 30kg. Approved by the US Food and Drug Administration (FDA) in March 2025, the spray is now ...

(RTTNews) - Satsuma Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved a 505(b)(2) New Drug Application (NDA) for Atzumi(dihydroergotamine (DHE)) nasal powder ...

If you have seasonal allergies, you might be miserable when springtime rolls around. As the temperatures warm and the flowers ...